WO2002038143A3 - Enhanced efficacy and safety of genotoxic therapy by p38 mapk modulation - Google Patents
Enhanced efficacy and safety of genotoxic therapy by p38 mapk modulation Download PDFInfo
- Publication number
- WO2002038143A3 WO2002038143A3 PCT/US2001/047669 US0147669W WO0238143A3 WO 2002038143 A3 WO2002038143 A3 WO 2002038143A3 US 0147669 W US0147669 W US 0147669W WO 0238143 A3 WO0238143 A3 WO 0238143A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mapk
- modulation
- safety
- enhanced efficacy
- genotoxic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002239578A AU2002239578A1 (en) | 2000-11-07 | 2001-11-06 | Enhanced efficacy and safety of genotoxic therapy by p38 mapk modulation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24691200P | 2000-11-07 | 2000-11-07 | |
US60/246,912 | 2000-11-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002038143A2 WO2002038143A2 (en) | 2002-05-16 |
WO2002038143A3 true WO2002038143A3 (en) | 2003-12-31 |
Family
ID=22932754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/047669 WO2002038143A2 (en) | 2000-11-07 | 2001-11-06 | Enhanced efficacy and safety of genotoxic therapy by p38 mapk modulation |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002239578A1 (en) |
WO (1) | WO2002038143A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1709965A3 (en) | 2001-07-11 | 2006-12-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating cytokine mediate diseases |
WO2005077983A2 (en) * | 2004-02-05 | 2005-08-25 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Modulating p38 kinase activity |
FR2874619B1 (en) * | 2004-08-25 | 2006-11-17 | Centre Nat Rech Scient Cnrse | NOVEL PHOSPHORYLATED PHOSPHATASE SEQUENCES OF CDC25B PHOSPHATASE, ANTIBODIES DIRECTED THEREFROM AND USES THEREOF |
CN110624108B (en) * | 2019-01-08 | 2022-04-05 | 浙江大学 | Application of Fas or ligand FasL thereof as target in preparation of antitumor drugs |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5863729A (en) * | 1996-07-09 | 1999-01-26 | Washington University | DNA sequences encoding human TcAK1 kinase |
WO2001009373A2 (en) * | 1999-07-30 | 2001-02-08 | Basf Bioresearch Corporation | Native cdc25 substrates, compositions and uses related thereto |
WO2001057206A2 (en) * | 2000-02-03 | 2001-08-09 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme |
-
2001
- 2001-11-06 WO PCT/US2001/047669 patent/WO2002038143A2/en not_active Application Discontinuation
- 2001-11-06 AU AU2002239578A patent/AU2002239578A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5863729A (en) * | 1996-07-09 | 1999-01-26 | Washington University | DNA sequences encoding human TcAK1 kinase |
WO2001009373A2 (en) * | 1999-07-30 | 2001-02-08 | Basf Bioresearch Corporation | Native cdc25 substrates, compositions and uses related thereto |
WO2001057206A2 (en) * | 2000-02-03 | 2001-08-09 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme |
Non-Patent Citations (8)
Title |
---|
BULAVIN D V ET AL: "Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation.", THE EMBO JOURNAL. ENGLAND 1 DEC 1999, vol. 18, no. 23, 1 December 1999 (1999-12-01), pages 6845 - 6854, XP002224351, ISSN: 0261-4189 * |
FURNARI B ET AL: "Cdc25 mitotic inducer targeted by chk1 DNA damage checkpoint kinase.", SCIENCE. UNITED STATES 5 SEP 1997, vol. 277, no. 5331, 5 September 1997 (1997-09-05), pages 1495 - 1497, XP002224352, ISSN: 0036-8075 * |
GRAVES P R ET AL: "The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 25 FEB 2000, vol. 275, no. 8, 25 February 2000 (2000-02-25), pages 5600 - 5605, XP002224350, ISSN: 0021-9258 * |
LEE J C ET AL: "P38 MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS-MECHANISMS AND THERAPEUTIC POTENTIALS", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 82, no. 2/3, May 1999 (1999-05-01), pages 389 - 397, XP000972766, ISSN: 0163-7258 * |
MORRIS M C ET AL: "An essential phosphorylation-site domain of human cdc25C interacts with both 14-3-3 and cyclins.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 15 SEP 2000, vol. 275, no. 37, 15 September 2000 (2000-09-15), pages 28849 - 28857, XP001118987, ISSN: 0021-9258 * |
PENG C Y ET AL: "Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216.", SCIENCE. UNITED STATES 5 SEP 1997, vol. 277, no. 5331, 5 September 1997 (1997-09-05), pages 1501 - 1505, XP002224349, ISSN: 0036-8075 * |
SANCHEZ Y ET AL: "Control of the DNA damage checkpoint by chk1 and rad53 protein kinases through distinct mechanisms.", SCIENCE. UNITED STATES 5 NOV 1999, vol. 286, no. 5442, 5 November 1999 (1999-11-05), pages 1166 - 1171, XP002224353, ISSN: 0036-8075 * |
WANG X ET AL: "Involvement of the MKK6-p38gamma cascade in gamma-radiation-induced cell cycle arrest.", MOLECULAR AND CELLULAR BIOLOGY. UNITED STATES JUL 2000, vol. 20, no. 13, July 2000 (2000-07-01), pages 4543 - 4552, XP002224348, ISSN: 0270-7306 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002239578A1 (en) | 2002-05-21 |
WO2002038143A2 (en) | 2002-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002080754A3 (en) | Methods for using annexin for detecting cell death in vivo and treating associated conditions | |
WO2001092581A3 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
WO2001073032A3 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
ID26620A (en) | OBSTACLES IN RAF KINASE USING SUBSTITUTED HETEROSICLIC URES | |
MXPA02010866A (en) | Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy. | |
WO2002069995A3 (en) | Use of trail and antiprogestins for treating cancer | |
AU2003274071A1 (en) | Dosage form that is safeguarded from abuse | |
WO2006065392A3 (en) | Cancer treatments | |
NZ333399A (en) | Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis | |
TR200100054T2 (en) | Paroxetine methanesulfonate | |
ZA992549B (en) | Incorporation of active substances in carrier matrixes. | |
WO2002004514A8 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
DK1392328T3 (en) | Medication for protection in radiotherapy | |
WO2002030465A3 (en) | Compositions that inhibit proliferation of cancer cells | |
WO2003053180A3 (en) | Undergarments containing active substances | |
HK1033910A1 (en) | Use of erythropoietin in the treatment of multiple myeloma | |
DE60008798D1 (en) | EXTRACT OF UNDIFFERENTIZED CELLS OF A LEONTOPODIUM PLANT AND COMPOSITIONS CONTAINING IT | |
WO2002038143A3 (en) | Enhanced efficacy and safety of genotoxic therapy by p38 mapk modulation | |
WO2002077263A3 (en) | Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon | |
TW332827B (en) | UV absorber | |
WO2001077168A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
WO2002039885A3 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
WO2000007616A3 (en) | Use of novel agents inducing cell death in synergy with interferons | |
AU1099699A (en) | Cell regulatory genes, encoded products, and uses related thereto | |
WO2001053524A3 (en) | Cancer associated genes and their products |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |